Fintel reports that on March 12, 2025, Ladenburg Thalmann downgraded their outlook for Zynex (NasdaqGS:ZYXI) from Buy to ...

Ladenburg downgraded Zynex (ZYXI) to Neutral from Buy without a price target saying the company continues to adjust operationally amid revenue ...

Germany’s Heidelberg Pharma (FSE: HPHA) has modified its royalty financing agreement with HealthCare Royalty (HCRx), securing an additional $20 million upfront payment. The amendment extends the ...

Q4 2024 Earnings Call Transcript March 12, 2025 Operator: Welcome to the Ondas Holdings Inc., Fourth Quarter and Full Year ...

Ladenburg lowered the firm’s price target on Ardelyx (ARDX) to $11 from $13.50 and keeps a Buy rating on the shares following a transfer of ...

Zynex specializes in non-invasive pain management and patient monitoring, with promising advancements. Read why I think ZYXI ...

Fidus Investment Corporation (NASDAQ: FDUS) (“Fidus” or the “Company”) today announced that it has priced an underwritten public offering of $100 million aggregate principal amount of 6.750% notes due ...

Creative Realities (NASDAQ:CREX – Get Free Report) is expected to announce its earnings results before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0 ...

ContractHeidelberg Pharma Amends Royalty Financing with HealthCare Royalty 13-March-2025 / 00:31 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, ...

UroGen Pharma (NASDAQ:URGN – Get Free Report) had its price target decreased by equities researchers at HC Wainwright from ...

Eric Brock; Chairman of the Board, President, Chief Executive Officer; Ondas Holdings Inc Neil Laird; Interim Chief Financial Officer, Treasurer and Secretary of the Company; Ondas Holdings Inc Markus ...

At this time I would like to welcome everyone to the WhiteHorse Finance fourth-quarter 2024 earnings conference call. Our host for today's call are Stuart Aronson, Chief Executive Officer; Joyson ...